Viking Therapeutics (VKTX) Cash from Operations (2014 - 2026)
Viking Therapeutics (VKTX) reported Cash from Operations of 113976000.0 for Q1 2026, down 117.8% on a YoY basis from 640377716.99 in Q1 2025, and down 33.63% sequentially from 85290000.0 in Q4 2025.
Viking Therapeutics (VKTX) Cash from Operations (2014 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 13 years of Cash from Operations data on file, last reported at 113976000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations fell 117.8% year-over-year to 113976000.0; the trailing twelve-month figure through Mar 2026 stood at 340330000.0 (down 154.0% YoY), and the FY2025 full-year result was 278685000.0, down 217.45% from the prior year.
- Cash from Operations declined to 113976000.0 in Q1 2026, from 85290000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 6134000.0 in Q1 2024 to a low of 113976000.0 in Q1 2026.
- A 5-year average of 35424941.18 and a median of 21962000.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations soared 75.11% in 2024 and slumped 753.13% in 2025, its largest moves.
- Tracing VKTX's Cash from Operations over 5 years: stood at 10926000.0 in 2022, then slumped by 61.45% to 17640000.0 in 2023, then tumbled by 76.76% to 31181000.0 in 2024, then sank by 173.53% to 85290000.0 in 2025, then plunged by 33.63% to 113976000.0 in 2026.
- Business Quant data shows VKTX's Cash from Operations at 113976000.0 in Q1 2026, 85290000.0 in Q4 2025, and 94003000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Viking Therapeutics | 4.09 Bn | 4.09 Bn | - | -113.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -113.98 Mn |
| Mar 31, 2026 | -113.98 Mn |
| Dec 31, 2025 | -85.29 Mn |
| Dec 31, 2025 | -85.29 Mn |
| Sep 30, 2025 | -94.00 Mn |
| Sep 30, 2025 | -94.00 Mn |
| Jun 30, 2025 | -47.06 Mn |
| Jun 30, 2025 | -47.06 Mn |
| Mar 31, 2025 | -52.33 Mn |
| Mar 31, 2025 | -52.33 Mn |
| Dec 31, 2024 | -31.18 Mn |
| Dec 31, 2024 | -31.18 Mn |
| Sep 30, 2024 | -21.96 Mn |
| Sep 30, 2024 | -21.96 Mn |
| Jun 30, 2024 | -28.51 Mn |
| Jun 30, 2024 | -28.51 Mn |
| Mar 31, 2024 | -6.13 Mn |
| Mar 31, 2024 | -6.13 Mn |
| Dec 31, 2023 | -17.64 Mn |
| Dec 31, 2023 | -17.64 Mn |